PMID- 11739812
OWN - NLM
STAT- MEDLINE
DCOM- 20020115
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 57
IP  - 11
DP  - 2001 Dec 11
TI  - HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple 
      sclerosis.
PG  - 1976-9
AB  - BACKGROUND: Copolymer 1 (Cop-1) is a random synthetic amino acid copolymer, 
      effective in the treatment of the relapsing-remitting form of MS (RRMS). In vitro 
      and in vivo studies suggest that the mechanism of Cop-1 involves its binding to 
      major histocompatibility complex class II molecules as an initial step. 
      OBJECTIVE: To assess a possible relationship between human leukocyte antigen 
      (HLA) alleles and response to Cop-1 therapy. METHODS: Eighty-three patients with 
      RRMS, 44 treated with Cop-1 and 39 with interferon beta-1a (IFNbeta-1a) for 2 
      years, were typed by molecular methods for HLA class II genes and subgrouped 
      according to clinical outcome. RESULTS: Data have shown a possible positive 
      correlation between presence of DRB1*1501 and response to Cop-1 therapy (p = 
      0.008). No relationship between HLA alleles and therapy has been found in 
      IFNbeta-1a treated patients. CONCLUSIONS: Results suggest that DRB1*1501 might be 
      relevant for the clinical outcome in Cop-1 treated patients and, if confirmed in 
      larger studies, it could be helpful in the selection of RRMS patients for 
      different therapeutic options.
FAU - Fusco, C
AU  - Fusco C
AD  - Servizio Immunoematologia e Trasfusione, Universita Fedrico II, Napoli, Italy.
FAU - Andreone, V
AU  - Andreone V
FAU - Coppola, G
AU  - Coppola G
FAU - Luongo, V
AU  - Luongo V
FAU - Guerini, F
AU  - Guerini F
FAU - Pace, E
AU  - Pace E
FAU - Florio, C
AU  - Florio C
FAU - Pirozzi, G
AU  - Pirozzi G
FAU - Lanzillo, R
AU  - Lanzillo R
FAU - Ferrante, P
AU  - Ferrante P
FAU - Vivo, P
AU  - Vivo P
FAU - Mini, M
AU  - Mini M
FAU - Macri, M
AU  - Macri M
FAU - Orefice, G
AU  - Orefice G
FAU - Lombardi, M L
AU  - Lombardi ML
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Peptides)
RN  - 5M691HL4BO (Glatiramer Acetate)
RN  - 77238-31-4 (Interferon-beta)
RN  - XRO4566Q4R (Interferon beta-1a)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Female
MH  - Glatiramer Acetate
MH  - HLA-DR Antigens/*genetics
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Interferon beta-1a
MH  - Interferon-beta/adverse effects/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/diagnosis/*drug therapy/genetics
MH  - Neurologic Examination/drug effects
MH  - Patient Selection
MH  - Peptides/adverse effects/*therapeutic use
MH  - Prognosis
EDAT- 2001/12/12 10:00
MHDA- 2002/01/16 10:01
CRDT- 2001/12/12 10:00
PHST- 2001/12/12 10:00 [pubmed]
PHST- 2002/01/16 10:01 [medline]
PHST- 2001/12/12 10:00 [entrez]
AID - 10.1212/wnl.57.11.1976 [doi]
PST - ppublish
SO  - Neurology. 2001 Dec 11;57(11):1976-9. doi: 10.1212/wnl.57.11.1976.